CoreLab Partners Now Offers Semi-automated ECG Solutions

PRINCETON, N.J., Oct. 24, 2011 /PRNewswire/ -- CoreLab Partners, Inc. has launched a new semi-automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions (A.M.P.S.) LLC.

"We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs," said CoreLab Partners' President and Chief Executive Officer, Dr. Mike Woehler. "This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform," added Woehler.  

The well-known AMPS CalECG application, originally designed for the on-screen measurement of ECG signals in the context of pharmaceutical trials, is capable of handling digital ECGs, seamlessly interfacing with several types of formats. The recently introduced version 3 of CalECG includes the new powerful measurement algorithm Bravo, as well as a diagnostic module assisting the user in the determination of important caliper positions.  

CoreLab Partners has also licensed the full set of AMPS Heart Rate Variability tools (WinHRV), which have been extensively used in the academic domain for the assessment of autonomic nervous systems changes associated with both clinical and drug-induced conditions. Fabio Badilini, PhD, FACC, Chief Scientist and AMPS founder, commented, "It is the first time that WinHRV will be implemented within a core lab organization, a sign that the effects of central nervous system are becoming an important facet of a number of new compounds. By adopting the WinHRV technology, CoreLab Partners continues to prove itself as a leading-edge provider of new technologies to the industry."

About CoreLab Partners, Inc.

CoreLab Partners, with offices in North America, Europe and Asia, provides comprehensive medical image assessment and cardiac safety services to the pharmaceutical, biotechnology and medical device industries. An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with full-time, board certified, sub-specialty trained radiologists, cardiologists, nuclear medicine physicians and oncologists. CoreLab Partners delivers disciplined solutions for the collection, analysis and management of patient images and cardiac safety & efficacy information during drug development. Driven by best-in-class science, emerging technologies and service quality, CoreLab is a global leader providing imaging sciences in all major modalities complemented by service offerings in the conduct of ECG, Thorough QT, Holter Monitoring, Ambulatory Blood Pressure Monitoring and Pulse Wave Analysis.

About A.M.P.S. LLC

A.M.P.S. LLC, based in New York, NY, is a leading-edge software company providing software solutions used specifically by clinical research organizations and pharmaceutical corporations in the field of quantitative ECG analysis and blood pressure monitoring and is well known for the support given to the FDA for the establishment of the HL7 XML ECG standard and for providing FDA officials with the famous AMPS XMLFDA Viewer tool. The company's website is http://www.amps-llc.com.

Contact:

Kevin D. Duffy
Vice President, Global Business Development
Email: [email protected]
Phone: 609-936-2600
http://www.corelabpartners.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CoreLab Partners, Inc.